Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Zonisamide (AD 810), a sulfonamide anticonvulsant, is approved for use as an adjunctive treatment in adults with partial-onset seizures. It may inhibit a carbonic anhydrase although this is not one of the main mechanisms of action. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels results in a reduction of T-type calcium channel currents, or by binding allosterically to GABA receptors. This latter action may lower the uptake of the inhibitory neurotransmitter GABA while increasing the uptake of the excitatory neurotransmitter glutamate.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
50 mg | In stock | $ 40.00 | |
100 mg | In stock | $ 59.00 | |
200 mg | In stock | $ 79.00 | |
500 mg | In stock | $ 134.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 50.00 |
Description | Zonisamide (AD 810), a sulfonamide anticonvulsant, is approved for use as an adjunctive treatment in adults with partial-onset seizures. It may inhibit a carbonic anhydrase although this is not one of the main mechanisms of action. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels results in a reduction of T-type calcium channel currents, or by binding allosterically to GABA receptors. This latter action may lower the uptake of the inhibitory neurotransmitter GABA while increasing the uptake of the excitatory neurotransmitter glutamate. |
Targets&IC50 | CA II (human):35.2 nM (Ki), CA V (human):20.6 nM (Ki) |
Synonyms | AD 810, CI 912 |
Molecular Weight | 212.23 |
Formula | C8H8N2O3S |
CAS No. | 68291-97-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 21.2 mg/mL (100 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Zonisamide 68291-97-4 Membrane transporter/Ion channel Metabolism Calcium Channel Carbonic Anhydrase Sodium Channel parkinson’s disease seizure epilepsy Carbonate dehydratase AD-810 Apoptosis Inhibitor cardiac hypertrophy AD 810 cardiac fibroblasts inhibit AD810 CI-912 CI912 NRCMs CI 912 SH-SY5Y inhibitor